Outrun TX develops a proprietary platform utilizing E3 ligase inhibition to stabilize tumor suppressor proteins, targeting hard-to-treat solid tumors in cancer therapy. This approach addresses the challenge of protein degradation pathways that undermine the effectiveness of existing cancer treatments.
Funding
$15.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many solid tumors are resistant to existing cancer therapies due to protein degradation pathways that destabilize tumor suppressor proteins, limiting the effectiveness of treatment. Current approaches often fail to address the underlying mechanisms that lead to the breakdown of these critical proteins.
Solution
Outrun Therapeutics is developing a platform that uses E3 ligase inhibition to stabilize tumor suppressor proteins, offering a novel approach to treating hard-to-treat solid tumors. By inhibiting specific E3 ligases, the platform aims to prevent the degradation of these proteins, thereby enhancing their tumor-suppressing activity. The company's lead program focuses on a small molecule inhibitor that targets an E3 ligase responsible for destabilizing a key tumor suppressor protein. This strategy seeks to empower the body's natural ability to fight cancer by preserving and enhancing the function of these protective proteins.
Target Audience
The primary target audience includes patients with hard-to-treat solid tumors, as well as pharmaceutical companies seeking innovative cancer therapies.
Features
- Proprietary platform for identifying and targeting E3 ligases involved in tumor suppressor protein degradation
- Small molecule inhibitors designed to selectively inhibit E3 ligase activity
- Focus on stabilizing key tumor suppressor proteins in hard-to-treat solid tumors
- Preclinical development programs focused on validating the efficacy and safety of E3 ligase inhibitors